Targeting SOX4 Shows Promise in Overcoming Sorafenib Resistance in Hepatocellular Carcinoma

Strategic Insights -

Research conducted at the First People's Hospital in Hangzhou, People's Republic of China, has identified SOX4 as a potential therapeutic target for overcoming sorafenib resistance in hepatocellular carcinoma (HCC). The study found that SOX4 expression was significantly elevated in sorafenib-resistant HCC cells and that targeting SOX4 could inhibit tumor growth and reduce immune infiltration.

Key Takeaways:

  • A sorafenib-resistant HCC cell line (SR-HepG2) was established by gradually increasing the sorafenib dose over 12 months.
  • The study found that SOX4 expression was significantly elevated in SR-HepG2 cells compared to parental HepG2 cells.
  • Targeting SOX4 through small interfering RNA (si-SOX4) reduced tumor growth and increased apoptosis in the sorafenib-resistant HCC mouse model.
  • The study also found that SOX4 knockdown inhibited the expression of immune escape markers and reduced immune cell infiltration in the tumor microenvironment.
  • The findings suggest that targeting SOX4 could be a promising therapeutic approach for overcoming sorafenib resistance in HCC.

Statistics:

  • After 12 months of gradual sorafenib dose increase, the SR-HepG2 cell line exhibited a 7-fold increase in sorafenib resistance compared to parental HepG2 cells.
  • The SOX4 expression level in SR-HepG2 cells was 3.5-fold higher than that in parental HepG2 cells.
  • Targeting SOX4 through si-SOX4 reduced tumor growth by 40% in the sorafenib-resistant HCC mouse model.
  • The study found that SOX4 knockdown inhibited the expression of immune escape markers by 25% in the sorafenib-resistant HCC mouse model.

Sources:

  • Sex-determining Region Y-box 4 Promotes the Progression of Advanced Hepatocellular Carcinoma and Enhances Regulatory T-cell Infiltration and Immune Suppression. Cytojournal, 2025;22:56.
  • BioMed Central - www.biomedcentral.com/
  • Cytojournal - archive.biomedcentral.com/1742-6413
  • Cancer Weekly. July 8, 2025; p 84.